TUSCALOOSA, AL — Jan. 15, 2025 — Crimson Tide Biomedical announced today it has raised $11 million in Series A funding, led by MedTech Ventures with participation from Southern Innovation Capital and a consortium of healthcare-focused angel investors. The round positions the Tuscaloosa-based company to advance its proprietary point-of-care diagnostic platform toward full commercialization. The company plans to deploy the capital across three strategic priorities: completing clinical validation trials for its flagship rapid-testing device, expanding its research and development team by approximately 30 employees, and scaling manufacturing operations at its University of Alabama Research Park facility. "This funding represents a pivotal moment for our team and for patients who deserve faster, more accurate diagnostics at the point of care," said CEO Dr. Marcus Webb. "We are building technology that can meaningfully reduce diagnosis-to-treatment timelines, particularly in underserved communities across the Southeast." Crimson Tide Biomedical's platform targets infectious disease detection, with current applications spanning respiratory illness, sepsis markers, and antimicrobial resistance screening. The company expects to submit its first device for FDA 510(k) clearance by the fourth quarter of 2025. Founded in 2020 as a spinout from the University of Alabama's biomedical engineering program, the company has previously secured $3.2 million in combined grant funding from the National Institutes of Health and the Alabama Department of Commerce. **About Crimson Tide Biomedical** Crimson Tide Biomedical is a Tuscaloosa, Alabama-based medical technology company developing rapid, point-of-care diagnostic solutions for infectious disease. Founded in 2020 and rooted in University of Alabama research, the company is committed to delivering faster clinical answers that improve patient outcomes across diverse healthcare settings. For more information, visit crimsontidebiomedical.com. ---